Nanoviricides (NNVC) Debt Ratio (2013 - 2023)

Nanoviricides (NNVC) posted Debt Ratio of 0.1 for Q3 2023, up 9.62% sequentially from 0.09 in Q2 2023, and up 8913.42% YoY from 0.0 in Q3 2022.

Nanoviricides (NNVC) Debt Ratio (2013 - 2023) Analysis & Trends

Nanoviricides has reported Debt Ratio for 9 years, with the latest figure at 0.1 in Q3 2023.

Quarterly Debt Ratio rose 8913.42% year-over-year to 0.1 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 0.1 (up 8913.42% YoY) and the FY2023 annual result came in at 0.09, up 2100.02% from the prior year.
Debt Ratio climbed to 0.1 in Q3 2023 per NNVC's latest filing, from 0.09 in the prior quarter.
Over five years, Debt Ratio peaked at 0.1 in Q3 2023 and troughed at 0.0 in Q3 2020.
A 4-year average of 0.02 and a median of 0.0 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2021 and 2023: Debt Ratio retreated 23.46% in 2021, then soared 8913.42% in 2023.
Over 4 years, Debt Ratio stood at 0.0 in 2020, then jumped by 65.47% to 0.0 in 2021, then surged by 31.42% to 0.0 in 2022, then jumped by 8913.42% to 0.1 in 2023.
According to Business Quant data, Debt Ratio over the past three periods registered 0.1, 0.09, and 0.0 for Q3 2023, Q2 2023, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Nanoviricides	28.74 Mn	25.53 Mn	-	-

Download Data